Edwards Lifesciences is a medical devices business based in the US. Edwards Lifesciences shares (EW) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $69.54 – an increase of 5.11% over the previous week. Edwards Lifesciences employs 19,800 staff and has a trailing 12-month revenue of around $6.3 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $69.54 |
|---|---|
| 52-week range | $58.93 - $96.12 |
| 50-day moving average | $67.43 |
| 200-day moving average | $80.10 |
| Wall St. target price | $76.39 |
| PE ratio | 25.5444 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $2.59 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $70.2 from 2024-11-19
| 1 week (2024-11-13) | 5.53% |
|---|---|
| 1 month (2024-10-18) | -0.10% |
| 3 months (2024-08-20) | 1.18% |
| 6 months (2024-05-20) | -21.81% |
| 1 year (2023-11-20) | 4.48% |
|---|---|
| 2 years (2022-11-18) | -6.45% |
| 3 years (2021-11-19) | 117.03 |
| 5 years (2019-11-20) | 81.41 |
Valuing Edwards Lifesciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edwards Lifesciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Edwards Lifesciences shares trade at around 26x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Edwards Lifesciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.1033. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Edwards Lifesciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.1 billion.
The EBITDA is a measure of a Edwards Lifesciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $6.3 billion |
|---|---|
| Operating margin TTM | 29.11% |
| Gross profit TTM | $4.3 billion |
| Return on assets TTM | 10.65% |
| Return on equity TTM | 19.14% |
| Profit margin | 65.86% |
| Book value | $16.18 |
| Market Capitalization | $39 billion |
TTM: trailing 12 months
We're not expecting Edwards Lifesciences to pay a dividend over the next 12 months.
Edwards Lifesciences's shares were split on a 3:1 basis on 31 May 2020 . So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences shares which in turn could have impacted Edwards Lifesciences's share price.
Over the last 12 months, Edwards Lifesciences's shares have ranged in value from as little as $58.93 up to $96.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences's is 1.12. This would suggest that Edwards Lifesciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.